SLC5A2 and hydrops fetalis: Previous studies from our laboratory and from others have shown that empagliflozin (EMPA), a highly selective SGLT2 inhibitor, improves cardiac glucose and fatty acid oxidation, increases cardiac efficiency and improves overall cardiac function after transverse aortic constriction (TAC)-induced HF (6–8).